# A Prospective Virtual Study to Evaluate the Longevity of IgG Antibodies in Individuals Exposed to COVID-19

> **NCT05042193** · — · COMPLETED · sponsor: **Everly Health** · enrollment: 1883 (actual)

## Conditions studied

- SARS-CoV-2 Acute Respiratory Disease

## Interventions

- **OTHER:** SARS-CoV-2

## Key facts

- **NCT ID:** NCT05042193
- **Lead sponsor:** Everly Health
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-19
- **Primary completion:** 2022-05-31
- **Final completion:** 2022-06-14
- **Target enrollment:** 1883 (ACTUAL)
- **Last updated:** 2022-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05042193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05042193, "A Prospective Virtual Study to Evaluate the Longevity of IgG Antibodies in Individuals Exposed to COVID-19". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05042193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*